< Back to latest news & events

News

Protect It Before You Promote It: IP Advice for MedTech Innovators

October 2025

Developed a new medical product? Check.

Got tickets to an exciting MedTech conference to show off your new product? Check.

Intellectual property? Pardon?

In the excitement of bringing a new MedTech product to market it can be easy to overlook or leave intellectual property issues until later. Don’t!

Intellectual property issues are best sorted out upfront and before any greater potential issues arise.

In developing your product, you may want, or need, to give it to focus groups and users to try and test so they can benefit from your product before it goes to market. You’ll need to be able to discuss your product with them and receive their feedback. They will need to be able to use and experience the product to evaluate it. You want to do this in an open and collaborative environment, but without jeopardising your intellectual property rights. This is much easier if it is understood, by everyone involved, what is confidential. Nobody wants to be looking over their shoulder wondering if a previous collaboration or focus group discussion will negatively impact a patent application.  You may worry that conversations about intellectual property ownership are tricky or potentially off putting to those you wish to work with, but issues that feel large at the outset are likely to evaporate on discussion – so be bold and have open, upfront, discussions about confidentiality and ownership so you know what is yours to protect.

The same goes for collaborators. If you identify who owns which aspects of the intellectual property at the start of the relationship and throughout the development process, it will be much easier to address any ownership matters, than having to rake it over and remember who came up with which element. Who wants to have an acrimonious conversation about the legal stuff afterwards, when you really want to get your new medical product out there and helping those who need it? No one.

Furthermore, improperly laying out relationships can result in poor outcomes when trying to protect the product. Can you prove you owns the intellectual property? Is an assignment in place transferring intellectual property to your company? Without a clear legal chain of ownership in place, any patent or design applications may be vulnerable to attack. It may be difficult to show you own an invention and are entitled to file patents for it. Despite how beneficial your new product is to patients, an unproven or unclear chain of ownership may cause your IP protection to fall down on a technicality.

If you are unsure what should be kept secret, what should be protected, or what you can more freely discuss during your product developments and marketing, HGF can help. We are experts in identifying any intellectual property you have, and devising and implementing protection strategies to help you avoid IP pitfalls.

Don’t let intellectual property issues get in the way of marketing and delivering your new medical product to those who need it. Be bold, have conversations up front and ensure you’ve laid the groundwork to make sure you’re protected. Then go and enjoy that conference.


This article was written by Patent Director Frazer Bye.

Latest updates

Protect It Before You Promote It: IP Advice for MedTech Innovators

Developed a new medical product? Check. Got tickets to an exciting MedTech conference to show off your new product? Check. Intellectual property? Pardon? In the excitement of bringing a new …

Read article

Agritech Thymes: The Bite of Implied Consent: Lessons from the Pink Lady Case

Can the supply of a plant variety without clear and defined restrictions on its use be an implicit consent to commercialise it? This case centres on the evidence required to …

Read article

IAM Global Leaders 2026

HGF is proud to announce that we have 3 partners listed as an IAM Global Leader 2026. To qualify for inclusion in the IAM Global Leaders, individuals must be ranked …

Read article

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Read article
Event - 5th November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Event details

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Read article

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Read article
Event - 14th October 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Event details